Alembic Pharmaceuticals revenue up by 18% to Rs. 1486 crores in Q-1 FY24

Spread the love
Alembic Pharmaceuticals

Alembic Pharmaceuticals revenue up by 18% to Rs. 1486 crores in Q-1 FY24.

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said“The company grew in all the business segments with India outperforming the market with 9% growth, Ex US generics grew 46%, API grew 31% and the US generics business grew 6%. We have also started commercializing products from our Oncology and Injectable Facilities

Operational Highlights

India Branded Business

·         Branded Business up by 9% to Rs. 524 Cr in the quarter.

·         Branded Business reflected growth of 11%* better than industry growth of 9%*.

·         Specialty therapies recorded growth of 12%* vis a vis industry growth of 7%*.

·         Acute therapies recorded growth of 16%* vis a vis Industry growth of 10%*. In Anti Infective, Industry has shown growth of 10%* where as Alembic recorded 19%* growth.

·         Animal Health business recorded growth of 11% over PY Q1.

* IQVIA Qtr June ’23

International Business

·         US Generics up 6% to Rs. 390 crores in the quarter.

·         Ex-US International Formulations grew 46% to Rs. 266 Crores in the quarter.

·         5 ANDA approvals received during the quarter; 184 Cumulative ANDA approvals.

·         5 ANDA filings during the quarter; Cumulative ANDA filings at 250.

API Business

·         API business grew 31% at Rs. 305 crores in the quarter.

·         131 cumulative DMF Filings.

About Author

Leave a Reply

Your email address will not be published. Required fields are marked *